Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer/Hospira Epogen Biosimilar Rejected; Relief For Amgen

This article was originally published in Scrip

Executive Summary

Pfizer Inc. sneaked the news into its quarterly earnings call on Oct. 27 that its newly acquired subsidiary Hospira Inc. had received a complete response letter earlier this month from the FDA for its epoetin alfa biosimilar – a product Amgen Inc. has been working desperately through the US court system to keep off the market for a little while longer.

Advertisement

Related Content

2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie

Related Companies

Advertisement
UsernamePublicRestriction

Register